The Brutalist Report - CNBC
system |
|
- Supreme Court lawyer Tom Goldstein rearrested as flight risk after hiding cryptocurrency, prosecutors say [465d]
- Elon Musk and investors offering $97.4 billion for control of OpenAI, WSJ reports [465d]
- Sell McDonald's on Monday's gains, Main Street Research investor says [465d]
- Trump gets high approval ratings for his first weeks, new CBS poll finds [465d]
- Wholesale egg prices have 'blown way past' record highs, analyst says [465d]
- A Roth IRA offers a 'longer runway for tax-free investing,' advisor says. Here's how to use it [465d]
- Google Calendar no longer includes start of Black History Month, Pride Month [465d]
- Man pleads guilty in hack of SEC's X account that claimed approval of bitcoin ETFs [465d]
- These 2 sectors lead the market — plus, Broadcom may have another custom chip partner [465d]
- Trump to pause enforcement of law banning bribery of foreign officials [465d]
- How a CEO's exit and a Jeep 'comeback' led to Stellantis being the only automaker to advertise during Super Bowl 59 [465d]
- Judge to consider extending pause on Trump's federal worker buyout plan [465d]
- Trump, Musk actions put America at risk of 'a form of default,' former Treasury chiefs warn [465d]
- We're adding to our position in a sliding stock and booking profits in a 2025 winner [465d]
- Nvidia tries to extend its recovery streak, and Home Depot gets a big endorsement [465d]
- What the end of the penny means for the economy, your piggy bank, and the way America prices items [465d]
- To pay for Trump's tax cuts, House Republicans could raise student loan bills for millions of borrowers [465d]
- Eight years after selling AppDynamics to Cisco, Jyoti Bansal is pursuing an unusual merger [465d]
- Trump takes aim at 'wasteful' government spending by ordering end to penny production [465d]
- GameStop, MicroStrategy shares rise after Ryan Cohen posts photo with Michael Saylor [465d]
- Steel and aluminum stocks surge on Trump plan to impose 25% tariffs on imports to U.S. [465d]
- Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma [466d]
Previous Day